Alirocumab New
* Required Fields.
Please complete the form below and you will get the price list in 1 minute.
* Required Fields.
Please complete the form below and we will contact you shortly.
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS No. | 1245916-14-6 | Cat. No. | BCP25199 |
Name | Alirocumab | ||
Synonyms | REGN 727; REGN-727; REGN727; SAR 236553; SAR236553; SAR-236553; | ||
SMILES | |||
Chemical Name | |||
Formula | C6472H9996N1736O2032S42 | M. Wt | 146000 |
Purity | 98% | Storage | Store at 4-8°C |
Description | Alirocumab works by inhibiting the PCSK9 protein. PCSK9 binds to the low-density lipoprotein receptor (LDLR) (which takes cholesterol out of circulation), and that binding leads to the receptor being degraded, and less LDL cholesterol being removed from circulation. Inhibiting PCSK9 prevents the receptor from being degraded, and promotes removal of LDL cholesterol from circulation. After subcutaneous administration of alirocumab, maximal suppression of free PCSK9 occurs within 4 to 8 hours and has an apparent half-life of 17 to 20 days. Inhibition is dose-dependent. The antibody is distributed through the circulation, and it is eliminated at low concentrations by binding to its target, and at higher concentrations through a proteolytic pathway. |
Recommend Products
More >Tags:Alirocumab supplier,Alirocumab purchase,Alirocumab manufacturer,Alirocumab distributor,Alirocumab cost,Alirocumab buy,Alirocumab for sale